PubRank

Nobuhisa Ueda

Author PubWeight™ 63.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 KEGG as a glycome informatics resource. Glycobiology 2005 11.05
2 Protein homology detection using string alignment kernels. Bioinformatics 2004 2.13
3 Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007 1.44
4 KCaM (KEGG Carbohydrate Matcher): a software tool for analyzing the structures of carbohydrate sugar chains. Nucleic Acids Res 2004 1.43
5 Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 2009 1.41
6 A novel representation of protein sequences for prediction of subcellular location using support vector machines. Protein Sci 2005 1.38
7 Graph kernels for molecular structure-activity relationship analysis with support vector machines. J Chem Inf Model 2005 1.35
8 Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011 1.17
9 Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011 1.04
10 Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007 1.00
11 Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.99
12 Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress? Prog Neuropsychopharmacol Biol Psychiatry 2007 0.97
13 Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum Psychopharmacol 2009 0.97
14 Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp Anim 2008 0.97
15 ProfilePSTMM: capturing tree-structure motifs in carbohydrate sugar chains. Bioinformatics 2006 0.97
16 Efficient tree-matching methods for accurate carbohydrate database queries. Genome Inform 2003 0.97
17 Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 2006 0.93
18 Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 2004 0.92
19 Pathophysiological analysis of female Spontaneously Diabetic Torii fatty rats. Exp Anim 2010 0.89
20 Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence. Hum Psychopharmacol 2009 0.89
21 Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008 0.89
22 Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 2003 0.89
23 Critical examination of a correlation between brain gamma-aminobutyric acid (GABA) concentrations and a personality trait of extroversion in healthy volunteers as measured by a 3 Tesla proton magnetic resonance spectroscopy study. Psychiatry Res 2010 0.88
24 A simple method for inferring strengths of protein-protein interactions. Genome Inform 2004 0.87
25 Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.87
26 Clustering under the line graph transformation: application to reaction network. BMC Bioinformatics 2004 0.86
27 Inferring strengths of protein-protein interactions from experimental data using linear programming. Bioinformatics 2003 0.86
28 Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009 0.86
29 Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005 0.85
30 Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010 0.85
31 Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 2009 0.84
32 An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychopharmacol 2005 0.84
33 Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 2011 0.84
34 Pancreatic function of spontaneously diabetic torii rats in pre-diabetic stage. Exp Anim 2009 0.82
35 Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2009 0.82
36 A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J Biol Psychiatry 2009 0.82
37 Application of a new probabilistic model for recognizing complex patterns in glycans. Bioinformatics 2004 0.81
38 Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes. Neuropsychiatr Dis Treat 2008 0.81
39 Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels. J Clin Psychopharmacol 2010 0.81
40 Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. World J Biol Psychiatry 2010 0.81
41 Adenocarcinoma arising below an ileoanal anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case. Surg Today 2007 0.80
42 Increase of plasma brain-derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment. Neuropsychiatr Dis Treat 2007 0.80
43 Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 2004 0.80
44 Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. Hum Psychopharmacol 2008 0.79
45 Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan. Psychiatry Res 2010 0.79
46 Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.79
47 [Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery]. Jpn J Antibiot 2006 0.79
48 Characterization of hepatic glucose metabolism disorder with the progress of diabetes in male Spontaneously Diabetic Torii rats. J Vet Med Sci 2008 0.79
49 Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2006 0.79
50 Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors. Bioorg Med Chem 2006 0.78
51 [Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder]. Seishin Shinkeigaku Zasshi 2010 0.78
52 Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report. Hum Psychopharmacol 2011 0.78
53 [Brain-derived neurotrophic factor (BDNF) and mood disorder]. Nihon Shinkei Seishin Yakurigaku Zasshi 2010 0.77
54 A case of late-onset Tourette's disorder successfully treated with aripiprazole: view from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF). World J Biol Psychiatry 2009 0.77
55 Interaction between fluvoxamine and cotinine or caffeine. Neuropsychobiology 2002 0.77
56 Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol 2010 0.77
57 N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. J Clin Pharmacol 2010 0.77
58 A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers. Int J Psychiatry Clin Pract 2010 0.77
59 Grapefruit juice-fluvoxamine interaction--is it risky or not? J Clin Psychopharmacol 2003 0.76
60 Trichotilliomania responding to low-dose fluvoxamine. Psychiatry Clin Neurosci 2009 0.75
61 Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. Int J Psychiatry Clin Pract 2009 0.75
62 Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Hum Psychopharmacol 2007 0.75
63 Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. Psychiatry Clin Neurosci 2007 0.75
64 [Therapeutic effectiveness of transcranial magnetic stimulation for intractable depressive disorders-- blood catecholamines and BDNF]. Seishin Shinkeigaku Zasshi 2007 0.75
65 Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. Hum Psychopharmacol 2008 0.75
66 No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations. Hum Psychopharmacol 2010 0.75